id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
EPA-R09-OAR-2022-0107-0037,EPA,EPA-R09-OAR-2022-0107,Air Quality State Implementation Plans; Approvals and Promulgations: Arizona; Maricopa County; Power Plants,Rule,,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T15:41:01Z,2022-28272,0,0,09000064855670ba
EPA-HQ-OPP-2020-0492-0031,EPA,EPA-HQ-OPP-2020-0492,"AAPCO August 16th, 2022 EPA-OPP Dicamba Meeting Minutes",Supporting & Related Material,Meeting Materials,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T19:27:02Z,,0,0,090000648554bf2a
EPA-HQ-OPP-2020-0267-0002,EPA,EPA-HQ-OPP-2020-0267,Glufosinate-Ammonium. Human Health Risk Assessment for Proposed Use of Glufosinate-Ammonium on Turfgrass,Supporting & Related Material,Risk Assessment,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T19:26:29Z,,0,0,0900006485569c21
EPA-R05-OAR-2018-0841-0004,EPA,EPA-R05-OAR-2018-0841,Sioux 2016-2020 1 Hour and 24 Hour Emissions Data and 99th Percentile Calculation,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T20:49:09Z,,0,0,09000064855321fb
EPA_FRDOC_0001-29123,EPA,EPA_FRDOC_0001,"Environmental Impact Statements; Availability, etc.",Notice,,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T13:02:58Z,2022-28438,0,0,0900006485564abb
EPA-R05-OAR-2018-0841-0003,EPA,EPA-R05-OAR-2018-0841,Regional Meteorological Data Processing Protocol EPA Region 5 and States August 2014 – DRAFT,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T20:48:25Z,,0,0,09000064855321fa
EPA-HQ-OPP-2021-0211-0006,EPA,EPA-HQ-OPP-2021-0211,AgChem1 95220 R Label,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T19:28:53Z,,0,0,090000648555f745
EPA-R05-OAR-2018-0841-0002,EPA,EPA-R05-OAR-2018-0841,"Illinois Alton Township 2010 SO2 Attainment Plan, 12/03/2018 submittal including Attachments B-C-D-E-G",Supporting & Related Material,State/Tribal Submittal,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T20:49:07Z,,0,0,0900006483a4475f
EPA-R05-OAR-2018-0841-0005,EPA,EPA-R05-OAR-2018-0841,Alton SO2 Nonattainment Plan TSD,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T20:48:49Z,,0,0,09000064855321fc
EPA-HQ-OPP-2020-0492-0030,EPA,EPA-HQ-OPP-2020-0492,Weed Science August 15th 2022 Dicamba Meeting EPA-OPP Notes,Supporting & Related Material,Meeting Materials,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T19:26:30Z,,0,0,090000648554ae4f
EPA-HQ-OPP-2021-0211-0005,EPA,EPA-HQ-OPP-2021-0211,AgChem1-EP1 - Label - 16 March 2022 - clean,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T19:29:02Z,,0,0,090000648555f744
EPA-HQ-OPP-2021-0211-0003,EPA,EPA-HQ-OPP-2021-0211,"Revised Environmental Risk Assessment in Support of the Registration of AgChem1, Containing 99.9% extract of Caesalpinia spinosa as its Active Ingredient AND AgChem1-EP1 Containing 99.9% extract of Caesalpinia spinosa as its Active Ingredient",Supporting & Related Material,Risk Assessment,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T19:27:59Z,,0,0,0900006485546cb0
EPA-HQ-OPP-2021-0211-0004,EPA,EPA-HQ-OPP-2021-0211,"Product Chemistry Review and Human Health Risk Assessment for FIFRA Section 3 Registrations of the Manufacturing-Use Product, AgChem1, and the End-Use Product AgChem1-EP1, Containing Extract of Caesalpinia spinosa (99.9%) as a New Active Ingredient.",Supporting & Related Material,Risk Assessment,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T19:28:21Z,,0,0,0900006485546cb3
EPA-HQ-OPP-2021-0211-0002,EPA,EPA-HQ-OPP-2021-0211,Public Participation for  Extract of Caesalpinia Spinosa New Active Ingredient,Other,Public Participation,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,2023-01-15T04:59:59Z,2023-01-11T19:29:04Z,,0,0,090000648556027b
EPA-HQ-OPP-2021-0211-0007,EPA,EPA-HQ-OPP-2021-0211,Proposed Registration Decision for the New Active Ingredient Extract of Caesalpinia Spinosa,Supporting & Related Material,Decision,2022-12-30T05:00:00Z,2022,12,,,2023-01-11T19:29:02Z,,0,0,090000648555f69c
EPA-R05-OAR-2018-0841-0001,EPA,EPA-R05-OAR-2018-0841,Proposed approval of the Illinois Alton Township 2010 SO2 Attainment Plan,Proposed Rule,,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,2023-01-31T04:59:59Z,2022-12-30T13:59:02Z,2022-28158,0,0,09000064855670c2
FDA-2022-P-1457-0023,FDA,FDA-2022-P-1457,180 Day Interim Response Letter from FDA CFSAN to American Olive Oil Producers Association,Other,Response(s),2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T17:49:39Z,,0,0,090000648556952a
FDA-2022-H-3338-0001,FDA,FDA-2022-H-3338,Complaint,Other,Complaint,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T16:29:53Z,,0,0,0900006485567eab
FDA-2014-E-1640-0005,FDA,FDA-2014-E-1640,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T13:52:12Z,,0,0,0900006485567135
FDA-2022-H-3337-0001,FDA,FDA-2022-H-3337,Complaint,Other,Complaint,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T15:57:24Z,,0,0,0900006485567403
FDA-2018-N-4626-0161,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T17:31:57Z,,0,0,09000064855689c6
FDA-2018-N-4626-0167,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T18:46:30Z,,0,0,09000064855699d4
FDA-2022-P-1457-0024,FDA,FDA-2022-P-1457,180 Day Interim Response Letter from FDA CFSAN to DEOLEO,Other,Response(s),2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T17:49:50Z,,0,0,0900006485569d96
FDA-2022-P-3387-0001,FDA,FDA-2022-P-3387,Citizen Petition from Pet Schooled,Other,Citizen Petition,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2023-03-08T14:36:01Z,,0,0,09000064855602cf
FDA-2022-H-3340-0001,FDA,FDA-2022-H-3340,Complaint,Other,Complaint,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T15:33:14Z,,0,0,0900006485567b26
FDA-2020-P-2322-0004,FDA,FDA-2020-P-2322,Final Response to Covington & Burling LLP from FDA CDER,Other,Agency Response,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T18:34:23Z,,0,0,090000648556a0ea
FDA-2022-H-3341-0001,FDA,FDA-2022-H-3341,Complaint,Other,Complaint,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T15:37:26Z,,0,0,0900006485567b2c
FDA-2022-H-3342-0001,FDA,FDA-2022-H-3342,Complaint,Other,Complaint,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T15:44:09Z,,0,0,09000064855673fd
FDA-2022-H-3345-0001,FDA,FDA-2022-H-3345,Complaint,Other,Complaint,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T15:07:54Z,,0,0,0900006485567215
FDA-2022-N-2375-0003,FDA,FDA-2022-N-2375,Authorization of Emergency Use of an In Vitro Diagnostic Device in Response to an Outbreak of Mpox; Availability,Notice,Announcement,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T16:46:00Z,2022-28460,0,0,0900006485564bf9
FDA-2018-N-4626-0162,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T17:54:50Z,,0,0,0900006485569107
FDA-2020-P-2236-0004,FDA,FDA-2020-P-2236,Final Response to Covington & Burling LLP from FDA CDER,Other,Agency Response,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T18:35:24Z,,0,0,0900006485569c1f
FDA-2018-N-4626-0168,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T18:54:27Z,,0,0,0900006485569a70
FDA-2018-N-4626-0163,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T18:18:03Z,,0,0,090000648556921f
FDA-2018-N-4626-0165,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T18:33:52Z,,0,0,09000064855694cd
FDA-2018-N-4626-0164,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T18:24:08Z,,0,0,0900006485569404
FDA-2022-H-3339-0001,FDA,FDA-2022-H-3339,Complaint,Other,Complaint,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T16:42:38Z,,0,0,0900006485568281
FDA-2022-H-3346-0001,FDA,FDA-2022-H-3346,Complaint,Other,Complaint,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T15:11:41Z,,0,0,0900006485567218
FDA-2022-H-3347-0001,FDA,FDA-2022-H-3347,Complaint,Other,Complaint,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T15:24:06Z,,0,0,0900006485567211
FDA-2022-P-1457-0025,FDA,FDA-2022-P-1457,180 Day Interim Response Letter from FDA CFSAN to North American Olive Oil Association,Other,Response(s),2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T17:50:01Z,,0,0,0900006485569e3b
FDA-2018-N-4626-0166,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T18:39:54Z,,0,0,09000064855694d0
FDA-2022-N-3188-0001,FDA,FDA-2022-N-3188,Medical Devices; Neurological Devices; Classification of the Pediatric Autism Spectrum Disorder Diagnosis Aid,Rule,Final Rule,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T15:50:59Z,2022-28430,0,0,0900006485564b47
FDA-2022-P-3387-0002,FDA,FDA-2022-P-3387,Acknowledgment Letter from FDA DMS to Pet Schooled,Other,Acknowledgement Letter/Receipt,2022-12-30T05:00:00Z,2022,12,2022-12-30T05:00:00Z,,2022-12-30T14:47:26Z,,0,0,0900006485560ef2
FWS-R6-ES-2022-0129-0003,FWS,FWS-R6-ES-2022-0129,Peer review comments_20220223_SSA,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:30:51Z,,0,0,090000648555fb2d
FWS-R6-ES-2022-0129-0005,FWS,FWS-R6-ES-2022-0129,PETITION_206 species Forest Guardians R6 7-24-07,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:30:53Z,,0,0,090000648555fb2f
FWS-R6-ES-2022-0131-0004,FWS,FWS-R6-ES-2022-0131,PECE analysis of 3milkvetches CAS_FINAL_20220520,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:31:51Z,,0,0,0900006485560e83
FWS-R6-ES-2022-0131-0007,FWS,FWS-R6-ES-2022-0131,Milkvetch CAS FINAL_SIGNED_20220520,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:31:55Z,,0,0,0900006485560e86
FWS-R6-ES-2022-0129-0004,FWS,FWS-R6-ES-2022-0129,PECE analysis of 3milkvetches CAS_FINAL_20220520,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:30:52Z,,0,0,090000648555fb2e
FWS-R6-ES-2022-0131-0006,FWS,FWS-R6-ES-2022-0131,SSA_CiscoMilkvetch_IselysMilkvetch_StageStationMilkvetch - See Attachments,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:31:53Z,,0,0,0900006485560e85
FWS-R6-ES-2022-0129-0007,FWS,FWS-R6-ES-2022-0129,Milkvetch CAS FINAL_SIGNED_20220520,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:30:55Z,,0,0,090000648555fb31
FWS-R6-ES-2022-0131-0005,FWS,FWS-R6-ES-2022-0131,PETITION_206 species Forest Guardians R6 7-24-07,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:31:52Z,,0,0,0900006485560e84
FWS-R6-ES-2022-0129-0006,FWS,FWS-R6-ES-2022-0129,SSA_CiscoMilkvetch_IselysMilkvetch_StageStationMilkvetch - See Attachments,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:30:54Z,,0,0,090000648555fb30
FWS-R6-ES-2022-0131-0003,FWS,FWS-R6-ES-2022-0131,Peer review comments_20220223_SSA,Supporting & Related Material,,2022-12-30T05:00:00Z,2022,12,,,2022-12-30T14:31:50Z,,0,0,0900006485560e82
EPA-HQ-OAR-2021-0427-0421,EPA,EPA-HQ-OAR-2021-0427,Renewable Fuel Standard Program: Standardsfor 2023-2025 and Other Changes,Proposed Rule,,2022-12-30T00:00:00Z,2022,12,2022-12-30T00:00:00Z,2023-02-11T04:59:59Z,2025-05-13T09:00:42Z,2022-26499,0,0,0900006485564bbb
APHIS-2019-0035-0002,APHIS,APHIS-2019-0035,Domestic Quarantine: Quarantined Areas and Regulated Articles,Rule,Final Rule,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T15:06:59Z,2022-27280,0,0,090000648555c7e6
EPA-R06-OAR-2022-0546-0008,EPA,EPA-R06-OAR-2022-0546,AR036.08 Arkansas MSW Landfills Plan IBR Approval Letter,Supporting & Related Material,,2022-12-29T05:00:00Z,2022,12,,,2023-01-01T08:55:26Z,,0,0,090000648554ae52
EPA-R06-OAR-2022-0546-0007,EPA,EPA-R06-OAR-2022-0546,"AR036.07 Approval and Promulgation of State Air Quality Plans for Designated Facilities and Pollutants; Arkansas; Control of Emissions From Existing Municipal Solid Waste Landfills, Final rule, 3 pages.",Rule,,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T16:23:06Z,2022-28154,0,0,090000648555c7b8
EPA_FRDOC_0001-29117,EPA,EPA_FRDOC_0001,"Proposed CERCLA Administrative Settlement Agreement: Removal Action by Prospective Purchaser and Proposed CERCLA Administrative Cost Recovery Settlement: Wells G and H Superfund Site, Woburn, MA",Notice,,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,2023-01-31T04:59:59Z,2023-01-30T02:00:40Z,2022-28310,0,0,090000648555c8d5
EPA-HQ-OW-2022-0834-0013,EPA,EPA-HQ-OW-2022-0834,National Pollutant Discharge Elimination System Small MS4 Urbanized Area Clarification,Proposed Rule,,2022-12-29T05:00:00Z,2022,12,,,2022-12-29T14:50:58Z,2022-28313,0,0,090000648555f17a
EPA-R09-OAR-2022-0815-0009,EPA,EPA-R09-OAR-2022-0815,E.1 87 FR 80076 FFA and Reclassification for 2012 PM2.5 NAAQS Plumas County CA,Supporting & Related Material,,2022-12-29T05:00:00Z,2022,12,,,2023-01-01T08:58:44Z,,0,0,090000648555f733
EPA-HQ-OW-2022-0834-0012,EPA,EPA-HQ-OW-2022-0834,National Pollutant Discharge Elimination System Small MS4 Urbanized Area Clarification,Rule,Direct Final Rule,2022-12-29T05:00:00Z,2022,12,,,2022-12-29T14:36:15Z,2022-28314,0,0,090000648555f5aa
EPA-R09-OAR-2022-0815-0007,EPA,EPA-R09-OAR-2022-0815,"Finding of Failure to Attain and Reclassification as Serious Nonattainment for the 2012 Annual Fine Particulate Standard: Plumas County, CA",Rule,,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T15:53:50Z,2022-28269,0,0,090000648555c8db
EPA-R09-OAR-2022-0815-0008,EPA,EPA-R09-OAR-2022-0815,Final Docket for Finding of Failure to Attain for Portola 2012 PM2.5 NAAQS,Supporting & Related Material,,2022-12-29T05:00:00Z,2022,12,,,2023-01-01T08:58:06Z,,0,0,090000648555f732
EPA-R08-OAR-2022-0846-0005,EPA,EPA-R08-OAR-2022-0846,12-22-2022_CWT Deep 10 1-2_EmailNotifAppComplete,Supporting & Related Material,,2022-12-29T05:00:00Z,2022,12,,,2023-01-01T08:57:05Z,,0,0,090000648555fa1c
EPA-R08-OAR-2022-0846-0004,EPA,EPA-R08-OAR-2022-0846,Email Correspondence EPA-Trinity CWT Deep 10 1-2 Revised app_12-20-22,Supporting & Related Material,,2022-12-29T05:00:00Z,2022,12,,,2023-01-01T08:56:25Z,,0,0,090000648555f7bf
FDA-2019-E-3295-0004,FDA,FDA-2019-E-3295,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T21:19:09Z,,0,0,090000648555f839
FDA-2022-N-3144-0001,FDA,FDA-2022-N-3144,Medical Devices; Orthopedic Devices; Classification of the Resorbable Implant for Anterior Cruciate Ligament (ACL) Repair,Rule,Final Rule,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T15:02:54Z,2022-28166,0,0,090000648555f5b1
FDA-2022-V-3370-0001,FDA,FDA-2022-V-3370,Variance Application from Klip Collective,Other,Application for Variance (VAR),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:51:33Z,,0,0,090000648555bfeb
FDA-2022-V-3370-0002,FDA,FDA-2022-V-3370,Acknowledgment Letter from FDA DMS to Klip Collective,Other,Acknowledgement Letter/Receipt,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:51:49Z,,0,0,090000648555b418
FDA-2022-V-3378-0002,FDA,FDA-2022-V-3378,Acknowledgment Letter from FDA DMS to Judd Lacson,Other,Acknowledgement Letter/Receipt,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:31:31Z,,0,0,090000648555c329
FDA-2018-N-4626-0160,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T22:26:13Z,,0,0,090000648555f9af
FDA-2022-H-3332-0001,FDA,FDA-2022-H-3332,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T16:14:46Z,,0,0,090000648555f2bb
FDA-2022-V-3373-0001,FDA,FDA-2022-V-3373,Variance Application from 4Grand Entertainment,Other,Application for Variance (VAR),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T13:36:55Z,,0,0,090000648555b322
FDA-2022-V-3374-0002,FDA,FDA-2022-V-3374,Acknowledgment Letter from FDA DMS to Anthony Risko,Other,Acknowledgement Letter/Receipt,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T13:54:07Z,,0,0,090000648555b37c
FDA-2022-V-3371-0001,FDA,FDA-2022-V-3371,Variance Application from Ralph Geronilla,Other,Application for Variance (VAR),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:57:59Z,,0,0,090000648555c32c
FDA-2022-V-3371-0002,FDA,FDA-2022-V-3371,Acknowledgment Letter from FDA DMS to Ralph Geronilla,Other,Acknowledgement Letter/Receipt,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:58:11Z,,0,0,090000648555c32f
FDA-2022-V-3372-0002,FDA,FDA-2022-V-3372,Acknowledgment Letter from FDA DMS to Music Lifeline Dj,Other,Acknowledgement Letter/Receipt,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T15:06:31Z,,0,0,090000648555bfe8
FDA-2018-N-4626-0159,FDA,FDA-2018-N-4626,Nomination from Wedgewood Pharmacy,Other,Nomination,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T22:23:39Z,,0,0,090000648555f97c
FDA-2022-H-3330-0001,FDA,FDA-2022-H-3330,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T17:54:49Z,,0,0,090000648555f4b9
FDA-2022-H-3204-0001,FDA,FDA-2022-H-3204,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T12:46:27Z,,0,0,090000648555bbc2
FDA-2022-H-3323-0001,FDA,FDA-2022-H-3323,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T13:02:29Z,,0,0,090000648555ed34
FDA-2022-H-3326-0001,FDA,FDA-2022-H-3326,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T13:57:14Z,,0,0,090000648555c75c
FDA-2022-V-3375-0001,FDA,FDA-2022-V-3375,Variance Application from Ashley Deleon,Other,Application for Variance (VAR),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:01:12Z,,0,0,090000648555bd30
FDA-2019-E-1978-0004,FDA,FDA-2019-E-1978,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T21:18:14Z,,0,0,090000648555fe31
FDA-2022-V-3377-0002,FDA,FDA-2022-V-3377,Acknowledgment Letter from FDA DMS to Eric Lopezdevictoria,Other,Acknowledgement Letter/Receipt,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:23:28Z,,0,0,090000648555bd36
FDA-2022-H-3322-0001,FDA,FDA-2022-H-3322,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T12:52:22Z,,0,0,090000648555ed2e
FDA-2022-V-3374-0001,FDA,FDA-2022-V-3374,Variance Application from Anthony Risko,Other,Application for Variance (VAR),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T13:49:39Z,,0,0,090000648555b379
FDA-2022-H-3307-0001,FDA,FDA-2022-H-3307,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T15:00:18Z,,0,0,090000648555f2b5
FDA-2022-V-3372-0001,FDA,FDA-2022-V-3372,Variance Application from Music Lifeline Dj,Other,Application for Variance (VAR),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T15:05:27Z,,0,0,090000648555b32a
FDA-2022-V-3375-0002,FDA,FDA-2022-V-3375,Acknowledgment Letter from FDA DMS to Ashley Deleon,Other,Acknowledgement Letter/Receipt,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:05:22Z,,0,0,090000648555bd33
FDA-2022-V-3376-0001,FDA,FDA-2022-V-3376,Variance Application from Elijah Maine,Other,Application for Variance (VAR),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:10:03Z,,0,0,090000648555bfed
FDA-2019-E-1972-0004,FDA,FDA-2019-E-1972,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T21:25:16Z,,0,0,090000648555faf0
FDA-2011-N-0656-1313,FDA,FDA-2011-N-0656,FDA ADUFA Meeting Transcript,Other,Transcript(s),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T16:40:59Z,,0,0,090000648555f2dc
FDA-2022-H-3097-0001,FDA,FDA-2022-H-3097,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T16:59:22Z,,0,0,090000648555f73d
FDA-2022-H-3214-0001,FDA,FDA-2022-H-3214,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T17:17:48Z,,0,0,090000648555f4b3
FDA-2022-H-3329-0001,FDA,FDA-2022-H-3329,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T17:49:55Z,,0,0,090000648555f737
FDA-2022-H-3327-0001,FDA,FDA-2022-H-3327,Complaint,Other,Complaint,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T13:52:57Z,,0,0,090000648555efdf
FDA-2022-N-3186-0001,FDA,FDA-2022-N-3186,Medical Devices; Cardiovascular Devices; Classification of the Extracorporeal System for Carbon Dioxide Removal,Rule,Final Rule,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:51:20Z,2022-28168,0,0,090000648555f54f
FDA-2022-V-3379-0002,FDA,FDA-2022-V-3379,Acknowledgment Letter from FDA DMS to Kevin Collins,Other,Acknowledgement Letter/Receipt,2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:39:08Z,,0,0,090000648555b497
FDA-2022-V-3379-0001,FDA,FDA-2022-V-3379,Variance Application from Kevin Collins,Other,Application for Variance (VAR),2022-12-29T05:00:00Z,2022,12,2022-12-29T05:00:00Z,,2022-12-29T14:35:24Z,,0,0,090000648555b494